Background The OPTIMAL study was the first study to compare efficacy and tolerability of the
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …

Gefiinib and erlotinib are two similar small molecules of selective and reversible epidermal
growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs), which have been approved …

After the discovery of activating mutations in EGFR, EGFR tyrosine kinase inhibitors (TKIs)
have been introduced into the first-line treatment of non-small-cell lung cancer (NSCLC). A …

Sensitizing mutations in epidermal growth factor receptor (EGFR) are associated with
positive responses to anti-EGFR-targeted therapy, leading to a new era of treatment for non …

Background EGFR mutations cause inconsistent response to EGFR tyrosine-kinase
inhibitors (TKI). To better understand these features, we reviewed all cases of EGFR …

Background Activating mutations in EGFR are important markers of response to tyrosine
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …

The development of EGFR tyrosine kinase inhibitors for clinical use in non-small cell lung
cancer and the subsequent discovery of activating EGFR mutations have led to an explosion …

Discovery of activating mutations in EGFR and their use as predictive biomarkers to tailor
patient therapy with EGFR tyrosine kinase inhibitors (TKIs) has revolutionised treatment of …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned …

Purpose An American Society of Clinical Oncology (ASCO) provisional clinical opinion
(PCO) offers timely clinical direction to ASCO's membership following publication or …